Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
5-Amino-1MQ vs Dulaglutide (Trulicity)
An educational, source-based comparison of 5-Amino-1MQ and Dulaglutide (Trulicity) — how each peptide works, what it's researched for, and what to know before going deeper.
Not a peptide but commonly grouped in peptide research. A selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in obese adipose tissue. Inhibition increases SAM and NAD+ availability, increasing adipocyte energy expenditure in animal models.
- Diet-induced obesity (rodent)
- White adipose tissue energy expenditure
- Age-related muscle function
- • Investigational; no human clinical trials yet.
- • Not FDA-approved.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
5-Amino-1MQ vs Dulaglutide (Trulicity) — Key differences
- Class: 5-Amino-1MQ is classified as Metabolic · Small Molecule, while Dulaglutide (Trulicity) is GLP-1 Agonist · Metabolic.
- Primary research focus: 5-Amino-1MQ — diet-induced obesity (rodent); Dulaglutide (Trulicity) — type 2 diabetes.
- Tag: Metabolic vs FDA-Approved · Metabolic.